Earnings Release

Care Medical Reports strong 2Q2026 revenues and net profit, driven by higher patient volumes and recovering GOSI activity, supporting 1H 2026 revenue growth

- In 2Q2026, revenue reached SAR 456 million, up 15% year-on-year and 18% quarter-on-quarter, driven by a strong rebound in GOSI referrals, insurance revenue growth, higher patient volumes and solid contributions across the Group's hospital network. This record performance lifted 1H 2026 revenue to SAR 844 million, up 8% year-on-year.
- Total patient count rose 20% year-on-year and 11% quarter-on-quarter to 280 thousand in 2Q 2026, with inpatient admissions up 17% to 9 thousand and outpatient visits up 20% to 271 thousand. Growth was particularly strong at Al Malaz and Al Rawabi, supported by the rebound in GOSI activity, bringing total patient count in 1H 2026 to 531 thousand, up 15% year-on-year.
- Gross profit increased 15% year-on-year to SAR 169 million in 2Q 2026, with the gross margin recovering to 37.1%, up from 31.6% in the prior quarter, supported by stronger revenue growth and an improved case and payor mix. This lifted gross profit for 1H 2026 to SAR 292 million, broadly stable year-on-year.
- EBITDA increased 22% year-on-year to SAR 135 million in 2Q 2026, with the margin expanding to 29.5% from 27.8%. In 1H 2026, EBITDA declined 3% year-on-year, yielding a margin of 26.8%.
- Net profit increased 18% year-on-year to SAR 94 million in 2Q 2026, with the net margin expanding to 20.6%, supported by stronger revenue growth and improved gross and operating profitability. 1H 2026 net profit declined 11% year-on-year, yielding a net margin of 17.3%, mainly reflecting the seasonal pressures recorded during the first quarter.
- Group-wide occupancy improved to 84% in 2Q 2026, up from 82% in the first quarter, mainly supported by improved utilization at Al Rawabi as GOSI activity normalized and at Al Salam as patient activity and procedure volumes increased.

Financial Highlights

	2Q2026	2Q2025	YoY, %	1H2026	1H2025	YoY, %
Revenue	456	398	+15%	844	783	+8%
Gross Profit	169	147	+15%	292	290	+0.4%
% Margin	*37.1%*	*37.1%*	*0.0 ppts*	*34.6%*	*37.1%*	*-2.5 ppts*
EBITDA	135	111	+22%	226	233	-3%
% Margin	*29.5%*	*27.8%*	*+1.7 ppts*	*26.8%*	*29.8%*	*-3.0 ppts*
Net Profit	94	80	+18%	146	165	-11%
% Margin	*20.6%*	*20.1%*	*+0.5 ppts*	*17.3%*	*21.1%*	*-3.8 ppts*

Riyadh, 30 July 2026 – Care Medical, a leading healthcare provider in Saudi Arabia, reported its financial results for the first half of 2026, highlighted by a record-breaking second quarter that marked a solid recovery from the seasonal softness witnessed at the start of the year.

Revenue for 1H 2026 reached SAR 844 million, up 8% year-on-year, supported by a 15% rise in total patient volumes to 531 thousand. The standout performance came in 2Q 2026, where revenue hit an all-time quarterly high of SAR 456 million, driven by a strong rebound in GOSI referrals, continued insurance revenue growth, and solid contributions across the hospital network.

The second quarter recovery carried through to profitability, with gross margin rebounding to 37.1%, EBITDA margin expanding to 29.5%, and net profit reaching SAR 94 million with an improved net margin of 20.6%, marking Care Medical's strongest operational quarter to date.

Capacity Expansions

Care Medical continues to advance its strategic expansion plans, with Al Narjis Hospital remaining a key pillar of the Group's organic growth pipeline. Construction of the 400-bed premium hospital in Northern Riyadh is progressing in line with plan, with the project on track to begin operations in 2028. The facility represents a planned investment of approximately SAR 1.4 billion.

Alongside Al Narjis, Care Medical is progressing its plan to add five to eight facilities by 2032 through greenfield developments, selective acquisitions and outpatient clinics. The pipeline includes a phased hospital development in Jeddah, with an initial capacity of 150 beds and further expansion planned as utilization builds, alongside the rollout of new clinics with the first clinic targeted for 2027, supporting the Group's expansion across Riyadh and the Western Province.

Dr. Abdulaziz bin Saleh Alobaid, Chief Executive Officer of Care Medical, said: "As we reach the mid-point of the year, we are pleased to report a remarkable second-quarter performance that confirms the recovery we anticipated and reinforces our confidence in the strength of Care Medical's business model and growth strategy. Following the seasonal slowdown at the start of the year, the strong rebound in GOSI referrals alongside accelerating patient volumes and continued insurance growth drove record quarterly revenue and net profit. Moreover, broad-based contributions across our hospital network demonstrate strong demand for the Group's expanding range of services and specialties.

Looking ahead, we remain focused on translating this momentum into sustainable growth. We will continue to optimize capacity and throughput across our existing network, deepen our relationships with key payors, and scale specialized and higher-value service lines. In parallel, we are advancing our expansion pipeline, including Al Narjis Hospital, our planned growth in the Western Province, and the rollout of new clinics, while continuing to evaluate selective acquisition opportunities. Together with our investments in technology, operational efficiency, and talent development, these initiatives will support the development of a more integrated and scalable healthcare platform and create lasting value for our patients and shareholders."

Jahanzeb Ahmed Khan, Chief Financial Officer of Care Medical, added: "Care Medical delivered a strong second quarter, with revenue reaching an all-time high of SAR 456 million and net profit hitting a record SAR 94 million — our best quarter to date. The rebound in GOSI referrals, improved case and payor mix, and continued patient volume growth drove a meaningful recovery in margins, with gross margin at 37.1% and EBITDA margin expanding to 29.5%.

While first-half margins reflect the pressures from earlier in the year, the second quarter marks a clear turning point. We remain focused on building on this momentum as we move through the remainder of the year."

Operational and Financial Review

Operating Indicator Highlights

	2Q2026	2Q2025	YoY, %	1H2026	1H2025	YoY, %
Inpatient Admissions	8,660	7,386	+17%	16,526	14,168	+17%
Outpatient Visits	270,960	225,676	+20%	514,318	446,116	+15%
Total Patients	279,620	233,062	+20%	530,844	460,284	+15%
Inpatient Days	90,635	86,533	+5%	177,895	171,823	+4%
Bed Capacity	1,189	1,128	+5%	1,189	1,128	+5%
Bed Occupancy Rate (%)	84%	84%	-0.3 ppts	83%	84%	-1.5 ppts
ALOS, Total (days)*	8.7	9.7	-10%	8.9	10.0	-10%
Number of surgeries	7,570	6,075	+25%	13,695	12,000	+14%

Notes:
* "ALOS, Total" represents the total average length of stay for inpatients at Care Medical's facilities, excluding Al Balad branch, the Group's long-term acute care facility

Care Medical recorded a 15% year-on-year increase in total patient count to 530,844 in 1H 2026, supported by a 15% rise in outpatient visits to 514,318 and a 17% increase in inpatient admissions to 16,526. Growth accelerated during the second quarter as GOSI referral activity normalized following the seasonal slowdown at the start of the year, with total patient volumes reaching 279,620, up 20% year-on-year and 11% quarter-on-quarter.

Outpatient visits growth in 1H 2026 was led by Al Malaz, where visits increased 29% year-on-year to 172,119, representing the largest absolute increase across the Group's facilities. Al Rawabi recorded 235,520 visits, up 7% year-on-year, while Al Salam and Al Haram delivered growth of 16% and 21%, respectively in 1H 2026. Outpatient growth was particularly visible in 2Q 2026, with visits rising 20% year-on-year and 11% quarter-on-quarter to 270,960, reflecting the strong rebound in GOSI activity and sustained demand across the network.

Inpatient admissions increased 17% year-on-year to 16,526 in 1H 2026, led by Al Rawabi and Al Salam, where admissions rose 9% and 31%, respectively. Al Malaz also delivered solid growth of 7%, adding 329 admissions during the six-month period. This momentum was lifted by a particularly strong second quarter, with admissions rising 17% year-on-year and 10% quarter-on-quarter to 8,660, reflecting the recovery in referral activity and the resumption of higher-acuity procedures following the seasonal slowdown.

In line with the increase in inpatient admissions and improved case mix, surgical procedures rose 14% year-on-year to 13,695 in 1H 2026. Growth accelerated significantly in the second quarter, with the number of surgeries rising 25% year-on-year and 24% quarter-on-quarter to 7,570, reflecting the resumption of elective procedures during the second quarter and stronger patient activity across the network.

Total inpatient days increased by 4% year-on-year to 177,895 in 1H 2026. Meanwhile, the average length of stay (ALOS), excluding Al Balad given its distinct long-term care model, declined to 8.9 days from 10.0 days in 1H 2025. At Al Rawabi and Al Malaz, the average length of stay decreased to 10.2 days from 11.0 days. The reduction reflects continued improvements in patient throughput and enables the Group to accommodate higher admissions within its existing capacity.

Care Medical continued to expand its capacity, with the total number of beds increasing 5% year-on-year to 1,189, reflecting capacity additions at Al Rawabi and ReLib. Group-wide occupancy averaged 83% in 1H 2026, slightly below 84% in 1H 2025, as growth in inpatient days was absorbed by the expanded bed capacity and lower ALOS. Occupancy recovered to 84% in 2Q 2026 from 82% in the previous quarter, primarily supported by improved utilization at Al Rawabi as GOSI activity improved, as well as at Al Salam in light of higher patient activity and procedure volumes.

Income Statement Highlights

SAR million	2Q2026	2Q2025	YoY, %	1H2026	1H2025	YoY, %
Revenue	456	398	+15%	844	783	+8%
Cost of revenue	(287)	(250)	+15%	(553)	(493)	+12%
Gross profit	169	147	+15%	292	290	+0.4%
Selling & marketing	(7)	(5)	+49%	(10)	(8)	+30%
General & administrative	(54)	(47)	+16%	(105)	(94)	+12%
Provisions & other	(1)	(11)	-91%	(7)	(7)	+6%
Total operating expenses	(62)	(63)	-0.3%	(122)	(108)	+13%
Operating profit (EBIT)	107	85	+26%	170	182	-7%
EBITDA	135	111	+22%	226	233	-3%
Net profit	94	80	+18%	146	165	-11%
Gross profit Margin	37.1%	37.1%	0.0 ppts	34.6%	37.1%	-2.5 ppts
EBIT Margin	23.4%	21.4%	+2.0 ppts	20.1%	23.3%	-3.2 ppts
EBITDA Margin	29.5%	27.8%	+1.7 ppts	26.8%	29.8%	-3.0 ppts
Net profit Margin	20.6%	20.1%	+0.5 ppts	17.3%	21.1%	-3.8 ppts
ROAE*	20.0%	18.7%	+1.2 ppts	15.8%	19.9%	-4.1 ppts
ROAA*	12.4%	12.5%	-0.1 ppts	10.1%	13.1%	-3.0 ppts

Notes:
* ROAE and ROAA are calculated based on 1H 2026 and 2Q 2026 net profit annualised, and are therefore not directly comparable to full-year return metrics

Care Medical delivered solid top-line performance in 1H 2026, with revenue increasing 8% year-on-year to SAR 844 million, primarily driven by a 15% rise in patient volumes to 531 thousand. Growth was broad-based across the Group's hospital network and supported by higher contributions from both key payor segments, with GOSI revenue rising 8% to SAR 319 million as referral activity recovered, alongside continued growth in insurance revenue. The first-half result was strengthened by a remarkable second-quarter performance, as the rebound in GOSI referrals, accelerating patient volumes and stronger contributions across the hospital network drove 2Q 2026 revenue to an all-time high of SAR 456 million, up 15% year-on-year and 18% quarter-on-quarter.

Revenue growth was recorded across both the inpatient and outpatient segments, with inpatient revenue increasing by 7% year-on-year to SAR 555 million in 1H 2026 and outpatient revenue rising by 7% year-on-year to SAR 189 million.[1]

[1] *Inpatient and outpatient revenue figures have been reclassified following a change in discount allocation methodology from a blended average to a per business unit basis, with no impact on total healthcare-services revenue.*

Cost of revenue increased 12% year-on-year to SAR 553 million in 1H 2026, primarily driven by higher staff costs as stronger patient volumes resulted in higher overtime and doctor incentive expenses, alongside the Group's continued investment in physicians and specialized services to support business growth. Rising costs also reflect increased spending on medicines and consumables in line with higher activity levels. Cost as a share of revenue accounted for 65.4% in 1H 2026 compared to 62.9% in 1H 2025. This translated into broadly stable gross profit of SAR 292 million, compared to SAR 290 million in the prior-year period, with the gross margin narrowing to 34.6% from 37.1% in 1H 2025.

Nevertheless, cost trends improved considerably in 2Q 2026, supported by stronger top-line growth and improved operating efficiencies. As such, the cost-to-revenue ratio posted 62.9% in 2Q 2026, unchanged from 2Q 2025 and down from 68.4% in 1Q 2026. This translated into a 15% year-on-year increase in gross profit to SAR 169 million, with the margin recovering to 37.1%, in line with 2Q 2025 and up from 31.6% in 1Q 2026.

Operating expenses increased 13% year-on-year to SAR 122 million in 1H 2026, primarily driven by higher selling, general and administrative (SG&A) expenses, which rose 13% to SAR 115 million, reflecting the Group's expanded operations. The six-month period also included an ECL provision of SAR 8.2 million, compared to SAR 7.6 million in 1H 2025. With gross profit remaining broadly stable and operating expenses increasing, operating profit declined 7% year-on-year to SAR 170 million. This filtered through to the EBITDA line, resulting in a 3% year-on-year decline to SAR 226 million and the EBITDA margin narrowing to 26.8% from 29.8%. Nevertheless, profitability improved significantly in 2Q 2026, supported by higher gross profit and a lower ECL charge of SAR 2 million, compared to SAR 11 million in 2Q 2025 and SAR 6 million in 1Q 2026. Consequently, EBITDA increased 22% year-on-year to SAR 135 million, with the margin expanding to 29.5% from 27.8%.

Net profit declined 11% year-on-year to SAR 146 million in 1H 2026, with the net profit margin narrowing to 17.3% from 21.1% in 1H 2025, reflecting lower operating profit and higher finance costs. However, the turnaround in operating performance during the second quarter carried through to the bottom line, lifting net profit by 18% year-on-year to achieve a quarterly record of SAR 94 million. The net margin came in at 20.6% versus 13.5% in the 1Q 2026 and above the 20.1% recorded in 2Q 2025.

Total Revenue by Hospital, 1H 2026



Total Revenue by Hospital, 1H 2025



At the facility level, the Group recorded broad-based revenue growth across its hospital network in 1H 2026, supported by higher patient volumes and the recovery in GOSI referral activity during the second quarter. The legacy facilities, Al Rawabi and Al Malaz, remained the largest contributors, accounting for approximately 43% and 40% of total revenue, respectively. Their performance benefited from the rebound in GOSI activity, which is primarily concentrated across these two hospitals. Al Malaz led the Group's growth, with revenue increasing 10% year-on-year to SAR 336 million, while Al Rawabi's revenue rose 3% to SAR 365 million. The remaining facilities also delivered higher revenues on growing patient volumes and continued ramp-up, with Al Salam up 7% to SAR 65 million, Al Haram increasing almost fivefold to SAR 17 million, ReLib rising 32% to SAR 8 million, and Al Balad remaining broadly stable at SAR 54 million.

Total Revenue by Payer, 1H 2026



Sustained GOSI Revenue Growth Despite Cyclical Referral Activity



At the payor level, GOSI remained the Group's largest revenue contributor in 1H 2026, with revenue increasing 8% year-on-year to SAR 319 million. The anticipated recovery in referral activity materialized in the second quarter, following the seasonal slowdown caused by Ramadan and Eid at the start of the year. GOSI revenue rebounded 44% quarter-on-quarter and 28% year-on-year to post a quarterly record of SAR 188 million in 2Q 2026, reversing the sequential declines recorded in 4Q 2025 and 1Q 2026 signaling that referral activity is normalizing as anticipated.

Insurance maintained its strong growth trajectory, with revenue increasing 23% year-on-year to SAR 221 million in 1H 2026 and its contribution to total revenue rising to 26% from 23% in 1H 2025. Insurance-linked revenue was particularly strong in the second quarter, with the segment's revenue up 24% year-on-year to SAR 117 million, reflecting the Group's ongoing efforts to diversify and optimize its revenue streams.

Cost Trends

SAR million	2Q2026	2Q2025	YoY, %	1H2026	1H2025	YoY, %
Salaries and benefits	174	155	+12%	341	305	+12%
Medicines and consumables	84	67	+25%	155	135	+15%
D&A	19	18	+8%	39	35	+11%
Repairs and maintenance	5	5	+7%	9	9	-1%
Rent, utilities and other	5	5	-4%	9	9	+1%
Total Cost of revenues	**287**	250	+15%	553	**493**	**+12%**
Selling & marketing	7	5	+49%	10	8	+30%
General & administrative	54	47	+16%	105	94	+12%
Provisions for ECL	2	11	-79%	8	8	+8%
Other	(1)	(0.3)	+381%	(1)	(1)	+22%
Total Operating Expenses	**62**	**63**	**-0.3%**	**122**	**108**	**+13%**
Total Expenses	**350**	313	+12%	675	**601**	**+12%**

In 1H 2026, Care Medical's total expenses increased 12% year-on-year to SAR 675 million, driven by a 12% increase in cost of revenue to SAR 553 million. The rise was primarily attributable to higher salaries and employee benefits, up 12% year-on-year, reflecting the Group's ongoing hiring activity and continued investment in medical talent, alongside a 15% increase in medicines and consumables in line with higher patient volumes. Cost growth accelerated in 2Q 2026 as activity picked up, with cost of revenue increasing 15% year-on-year to SAR 287 million, mainly driven by a 25% rise in medicines and consumables, while salaries and employee benefits increased 12%.

Operating expenses increased 13% year-on-year to SAR 122 million in 1H 2026, primarily driven by higher selling, general and administrative expenses, which rose 13% to SAR 115 million, reflecting the Group's expanded operations and higher professional fees for advisors and consultants. The ECL provision remained broadly stable at SAR 8 million. However, cost trends improved significantly in 2Q 2026, with operating expenses remaining broadly stable year-on-year at SAR 62 million despite higher SG&A expenses. This was mainly supported by a 79% decline in ECL provisions to SAR 2 million from SAR 11 million in 2Q 2025.

EBITDA and Net Profit

SAR million	2Q2026	2Q2025	YoY, %	1H2026	1H2025	YoY, %
EBITDA	**135**	111	+22%	226	**233**	**-3%**
Depreciation & amortization	(28)	(26)	+9%	(57)	(51)	+11%
Finance income / (cost)	(6)	(2)	+230%	(10)	(4)	+157%
Zakat expense	(7)	(3)	+112%	(13)	(13)	+2%
Net Profit	**94**	**80**	**+18%**	**146**	**165**	**-11%**

Care Medical's EBITDA declined 3% year-on-year to SAR 226 million in 1H 2026, with the EBITDA margin narrowing to 26.8% from 29.8%, reflecting the gross profitability pressures and higher operating expenses recorded during the first quarter. However, 2Q 2026 marked a clear turnaround, as stronger gross profit and lower ECL provisions drove EBITDA up 22% year-on-year to SAR 135 million. The EBITDA margin recovered to 29.5%, compared to 27.8% in 2Q 2025 and 23.6% in the previous quarter.

Net profit declined 11% year-on-year to SAR 146 million in 1H 2026, with the net profit margin narrowing to 17.3% from 21.1%. The decline reflected lower operating profitability during the first quarter, alongside higher depreciation and finance costs. Nevertheless, the improvement in operating performance during 2Q 2026 carried through to the bottom line, with net profit increasing 18% year-on-year to a record SAR 94 million, despite higher finance costs and Zakat expenses. The net profit margin expanded to 20.6%, compared to 20.1% in 2Q 2025 and 13.5% in the previous quarter.

Cash Flow Highlights

SAR million	2Q2026	2Q2025	YoY, %	1H2026	1H2025	YoY, %
Net Profit before zakat	**101**	83	+21%	160	**178**	**-10%**
Non-cash adjustments	45	44	+2%	93	75	+24%
Working capital changes	(201)	(179)	+13%	(330)	(145)	+127%
Zakat, finance income, and end-of-service benefits	(36)	(25)	+43%	(42)	(27)	+56%
Net cash, operations	**(92)**	(77)	+19%	(120)	**80**	**NA**
Capex	(104)	(25)	+311%	(156)	(48)	+225%
Net cash, investing activities	**(104)**	50	NA	(105)	**255**	**NA**
Net cash, financing activities	**(66)**	(98)	-32%	(12)	**(122)**	**-91%**
Net changes in cash	**(262)**	(125)	+110%	(237)	**213**	**NA**

Care Medical recorded a net cash outflow from operating activities of SAR 120 million in 1H 2026, compared to an inflow of SAR 80 million in 1H 2025. The year-on-year change was primarily driven by a significant increase in working capital requirements, booking an outflow of SAR 330 million compared to SAR 145 million in the prior year period, alongside higher Zakat, finance costs and end-of-service benefit payments. The working capital movement was primarily driven by a SAR 284 million cash outflow related to trade and other receivables, compared to SAR 124 million in 1H 2025, as higher billings following the recovery in GOSI activity during the second quarter outpaced collections. It is worth highlighting that the Group collected SAR 150 million from GOSI and the Ministry of Health during the second quarter of 2026, with a further SAR 118 million received subsequent to the quarter end.

Net cash used in investing activities amounted to SAR 105 million in 1H 2026, compared to a SAR 255 million in 1H 2025. Capital expenditure expanded to SAR 156 million, primarily reflecting continued investment in Al Narjis Hospital and the Group's existing network. This was partly offset by SAR 51 million received from maturing term deposits. The prior year period benefited from SAR 303 million in term-deposit maturities, resulting in a significantly higher investing inflow.

Net cash used in financing activities amounted to SAR 12 million in 1H 2026, compared to SAR 122 million in 1H 2025. The significantly lower outflow reflected SAR 285 million in loan proceeds, which absorbed most of the loan repayments; dividend and lease payments totalling around SAR 296 million.

As a result of these factors, Care Medical recorded a net decrease in cash and cash equivalents of SAR 237 million in 1H 2026, with its cash balance standing at SAR 243 million as of 30 June 2026.

Balance Sheet Highlights

SAR million	2Q2026	4Q2025	YtD, %
Total Non-Current Assets	1,553	1,291	+20%
Total Current Assets	1,479	1,480	-0.1%
Total Assets	**3,032**	2,771	**+9%**
Total Equity	**1,863**	**1,849**	**+1%**
Total Non-Current Liabilities	874	577	+51%
Total Current Liabilities	295	344	-14%
Total Liabilities	**1,169**	**922**	**+27%**
Cash, equiv. & time deposits	243	531	-54%
Net Debt[2]	556	(15)	NA
Days Sales Outstanding[3]	202	158	+28%
Days Payable Outstanding[2]	78	95	-18%
Days Inventory Outstanding[2]	73	71	+3%
Cash Conversion Cycle[2]	197	134	+47%

As of 30 June 2026, Care Medical's total assets increased 9% year-to-date to SAR 3.0 billion. Non-current assets rose 20% year-to-date to SAR 1.6 billion, primarily reflecting continued capital expenditure on Al Narjis Hospital and the recognition of additional right-of-use assets. Current assets remained broadly stable at SAR 1.5 billion, reflecting a 31% year-to-date increase in trade receivables, as higher billings following the recovery in GOSI activity and continued insurance growth outpaced collections.

Total liabilities increased 27% year-to-date to SAR 1.2 billion, driven by a 51% increase in non-current liabilities following higher long-term borrowings to support the development of the Group's Al Narjis Hospital, alongside higher lease liabilities. Meanwhile, current liabilities declined 14% to SAR 295 million, mainly reflecting lower trade payables and short-term loan obligations. Gross borrowings and lease liabilities increased to approximately SAR 798 million from SAR 516 million at year-end 2025, while cash, cash equivalents and term deposits declined to SAR 243 million from SAR 531 million. Consequently, the Group moved from a net cash position of SAR 15 million at year-end 2025 to net debt of SAR 556 million as of 30 June 2026.

Working capital metrics continued to reflect slower cash conversion during the period. Days sales outstanding increased to 202 days from 158 days at year-end 2025, as higher billings following the recovery in GOSI activity and continued insurance growth outpaced collections. At the same time, days payable declined to 78 days from 95 days, reflecting faster payments to suppliers, while days inventory outstanding remained broadly stable at 73 days. Consequently, the cash conversion cycle lengthened to 197 days from 134 days, indicating that the improvement in operating activity had not yet fully translated into cash collections.

[2] Including time deposits
[3] Based on YTD indicators. DPO, DSO, and DIO are calculated based on Care methodology

Earnings Call

The company is hosting an earnings call to discuss 2Q 2026 financial results with analysts and investors on Thursday, 30 July 2026, at 16:00 Riyadh time (14:00 London, 17:00 Dubai, 09:00 New York).

Webcast link: Care Medical 2Q 2026 webcast

Institutional Investor Contact

Alia Balbaa
Investor Relations and Strategy Director
abalbaa@care.med.sa
+966-11-418-4488 ext. 322

For more details, please visit the Investor Relations Website

https://ir.care.med.sa/

Corporate Headquarters Address

Care Medical
P.O. Box 29393,
Riyadh, 11457,
Kingdom of Saudi Arabia

About Care

Care Medical (Care, Tadawul: 4005) is a leading healthcare provider based in Riyadh, Kingdom of Saudi Arabia. The company operates multiple facilities, including two full-service hospitals in Riyadh – Rawabi and Malaz – as well as Haram branch, an emergency department in Mecca's Grand Mosque area. Its network also includes Al Balad branch in Jeddah, specializing in long-term nursing, hospice, and palliative care, and the recently acquired Al Salam general hospital in Riyadh. In 2024, Care Medical expanded its service offerings with the launch of the ReLib mental health platform.

With a team of more than 4,300 healthcare practitioners, administrators, and support staff, Care Medical treated over 900 thousand patients and performed over 24 thousand surgeries in FY 2025. The company reported revenue of SAR 1.6 billion (+24% year-on-year), an EBITDA of SAR 465 million (29.1% margin), and a net profit of SAR 318 million (19.9% margin).